>>The NOPAIN Act is not a trend -- it's a possible future catalyst, like the NHS and FDA full-body OTC clearance and Synergy were possible future catalysts. <<<
>>>No truer words were ever spoken! Very well said. This company has NOT capitalized on ANY of those 5 USA FDA clearances and the NHS was a failure and ..... drum roll please......where is SYNERGY?<<<
————————————————————————————————————-
The attempted marriage of the NOPAIN Act/CMS to the failure to capitalize on the 5 FDA approvals, and all the other “failures”, as a predictor for BIEL’s next failure in light of The Act/CMS, is wholly misguided, imo.
No, no, and no. The logic does not follow.
Was the NOPAIN Act on the radar of Congress for approval/being discussed/passed, along with CMS insurance reimbursement possibility, for non-opioid treatment alternatives during the “failure to capitalize” 5 FDA clearances and whatnot?
No, no, and no.
The NOPAIN Act has everything to do with BIEL’s possible future success…IF…established companies in the Pain Arena see the company as a conduit to a long-term lucrative money stream given The NOPAIN Act/CMS insurance reimbursement possibility.
Interested companies in the Pain Arena, if any, will decide on the value of BIEL. “They” will have to compete amongst themselves FIRST which will drive up BIEL’s “inherent” value, with that value being finally known when the “i’s” are dotted and “t’s” are crossed.
It is now NOT about what BIEL could or could not do as in the PAST. It is NOW about what the established biggies in the Pain Arena will do, if anything, concerning BIEL.
BIEL is worth a reasonable investment, not in and of itself, but worth it because of what OTHERS might be up to, and actually do.
No one knows what will happen. Maybe nothing will happen. Who here has an “in” as to what these moneyed, muscled, savvy, politically involved, and well-established companies in the Pain Arena are doing?
The new crystal ball dubbed “The Act” is available for use in regards to BIEL’s possibilities.
The one used prior is chipped and now of no value.
All imo.
Market Data 
Markets 
AI
